CyberKnife(R) System Shows Momentum as Treatment Option for Prostate Cancer

Accuray Achieves Patient Treatment Milestone on Third Anniversary of National Prostate Cancer Awareness Month

SUNNYVALE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that more than 1,000 men have been treated for prostate cancer with the CyberKnife(R) Robotic Radiosurgery System. As the number of facilities worldwide offering CyberKnife treatments has grown more than 65 percent in the last year, the CyberKnife System is showing tremendous momentum as an alternative to surgery or other conventional prostate cancer treatments.

September is National Prostate Cancer Awareness Month in the United States, which began in 2005 as the Bush Administration renewed its commitment to fight prostate cancer by finding better ways to prevent, detect and treat a disease that is the leading cause of cancer death in men. Prostate cancer is the most common cancer in men in the United States and the second most common in men worldwide. The American Cancer Society estimates that almost 219,000 new cases of prostate cancer will be diagnosed in the United States this year and more than 27,000 men will die from the disease.

"In this month dedicated to raising awareness about prostate cancer prevention and treatment, Accuray wants to make sure that people are well-informed about the variety of treatment options available to them today," said Eric Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. "More and more patients are turning to the Internet to find information on their cancer treatment options. And because of the CyberKnife System's success in treating prostate cancer non-invasively, many patients are referring themselves to CyberKnife centers for treatment."

Side effects often associated with prostate cancer treatments may include incontinence, erectile dysfunction, fatigue, anemia, nausea, bone pain and weakness. With the CyberKnife System, patients experience little to no side effects due to the System's ability to deliver high doses of radiation with extreme accuracy. The CyberKnife System's ability to track, detect and correct for tumor and patient movement during treatment, enables the CyberKnife System to avoid damaging surrounding healthy tissue and critical structures such as the urethra, rectum, prostate gland and neurovascular bundles responsible for the erectile function.

"Because CyberKnife treatments are non-invasive and the radiation delivery is extremely precise, patients lessen their likelihood of experiencing many of the life-altering side effects associated with conventional prostate cancer treatments," said Alan J. Katz, M.D. Director of Radiation Oncology, Winthrop University Hospital in Mineola, NY. "With CyberKnife treatments we are seeing excellent tumor response with minimal to no complications or side effects."

The CyberKnife System also offers patients more convenience than conventional treatments. Because it safely uses high doses of radiation, treatment with the CyberKnife System can be completed in one to five outpatient sessions, each lasting about an hour. Radiation and chemotherapy can takes weeks or months to complete, while surgery requires a significant

recovery period. With the CyberKnife System patients can typically return to their normal activities immediately following treatment.

"The diagnosis and treatment of prostate cancer can have devastating, life-long effects on men," said Ron Spears, who was treated for prostate cancer with the CyberKnife System in 2006. "With the CyberKnife, doctors were able to successfully treat my prostate cancer in five easy, one-hour sessions. More importantly, I wasn't sidelined with a long recovery or painful complications. In fact, after each treatment, I'd go out for coffee and then head to the golf course to play 18 holes."

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system cleared by the FDA to treat tumors anywhere in the body non-invasively and with sub-millimeter accuracy. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver precise, high-dose radiation, minimizing damage to surrounding healthy tissue and eliminating the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 35,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals and centers in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release regarding procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the fiscal year ended June 30, 2007 as may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
09/25/2007
CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,
susan@rockpointpr.com, for Accuray Incorporated; Stephanie Tomei, Public
Relations Manager of Accuray Incorporated, +1-408-789-4234,
stomei@accuray.com
Web site: http://www.accuray.com